ImmuPharma PLC New Phase III Lupuzor Trial Data Positive – May 2018

Chairman Tim McCarthy talks to DirectorsTalk about the further analysis of the results from its pivotal Phase III trial of Lupuzor and final results.

ImmuPharma chairman more optimistic on results for its Lupuzor drug – May 2018

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) tells Proactive that there is a strong indication that in certain populations of lupus patients, its Lupuzor drug works very effectively.  McCarthy was talking after a deeper dive into the data generated…

 

 

Immupharma PLC still confident on Lupuzor’s future – 19th April 2018

ImmuPharma PLC (LON:IMM) CEO Dimitri Dimitriou and chairman Tim McCarthy discuss with Proactive Investors the top-line results from their phase III trial of the drug Lupuzor.

Chairman Q&A with Tim McCarthy at ImmuPharma PLC (LON:IMM) – April 2018

ImmuPharma PLC (LON:IMM) Chairman Tim McCarthy caught up with DirectorsTalk for an exclusive interview to discuss the topline results of their Lupuzor Phase III trial. For full transcript click here

Vox market audio interview with Immupharma Chairman Tim McCarthy – 19th April 2018

Tim McCarthy, Chairman of Immupharma discusses the topline results of the Lupuzor Pivotal Phase III Trial.

Tim McCarthy talks to Proactive Investor on 2 February 2018

A great start to 2018 with pivotal Phase III data for Lupuzor™ only weeks away.

Interview with Tim McCarthy, Chairman of Immupharma – 19 Jan 2018

Tim McCarthy, Chairman of Immupharma discusses the completion of Lupuzor™ pivotal phase III study and initiation of follow up study.

Q&A with Vadim Alexandre Head of Research at Northland Capital Partners

ImmuPharma PLC (LON:IMM) is the topic of conversation when Northland Capital Partners Head of Research Vadim Alexandre caught up with DirectorsTalk for an exclusive interview.

Click here

Immupharma Plc On Track, Looking Good and Excited – 18th May 2017

Tim McCarthy talks to DirectorsTalk about its Lupuzor market update. Tim explains the main points to the update, the importance of reaching a milestone where all patients have been dosed for over three months, the importance of announcements to shareholders and confidence of providing top line results in Q1 2018.

Tim McCarthy updates on Phase III study – 17th May 2017

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) tells Proactive they’re on schedule to publish first results from their phase III trial of lupus drug Lupuzor early next year with all 200 patients now having had at least three months worth of treatment.

Tim McCarthy, Chairman of ImmuPharma – 17th May 2017

Tim McCarthy, Chairman of ImmuPharma gives an update, on its lead compound, Lupuzor™ in its pivotal Phase III study on this audio podcast

Biotech Capital Conference: 6th February 2017

Tim McCarthy, Chairman of ImmuPharma PLC , presents at the Biotech Capital Conference: 2017

Tim McCarthy talks to Proactive Investors – 6th February 2017

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) spoke to Proactive Investors to give an update on the company’s progress with its phase-III clinical trial of Lupuzor™, a treatment for Lupus – a life threatening auto-immune disease.

 

 

Tim McCarthy, Chairman of ImmuPharma #IMM – 26th January 2017

Tim McCarthy, Chairman of ImmuPharma talks to Vox Markets and gives update on their, Phase III Clinical Trials for its lead drug Lupuzor™.

 

Immupharma Plc – A multi-billion dollar selling drug

Immupharma Plc (LON:IMM) Non-Executive Chairman Tim McCarthy talks to DirectorsTalk about its phase 3 trial of Lupuzor. Tim explains the importance of completing the recruitment of the 200 patients and stay on track, the significance of the 70 patients that are being dosed in the US, detail on the Lupuzor safety profile and its importance, the market potential of Lupuzor if approved and key milestones for ImmuPharma in 2017/2018.

Director’s Talk interview